Kyverna Therapeutics
NASDAQ: KYTXEmeryville, US · Founded 2018 · 174 employees on LinkedIn · 8 known investors
Find your way into Kyverna Therapeutics
66 people in our graph share verified history with the Kyverna Therapeutics team — schools, employers, funds. One of them is your warm intro.
Desmond Padhiunlockedknows Warner Biddle · together at University of Saskatchewan (overlapped)
×11knows the team · via University of Saskatchewan
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Founders & leadership
WB
Warner Biddlein𝕏Chief Executive OfficerWarner Biddle is Chief Executive Officer of Kyverna Therapeutics, a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. He has over 30 years of experience in life sciences and therapeutic development across the United States, Europe, and Canada.
BK
Brian KotzinNamed on SEC filing
IC
Ian ClarkNamed on SEC filing
RJ
Ryan JonesNamed on SEC filing
KW
Karen WalkerNamed on SEC filing
PM
JC
James ChungNamed on SEC filing
DS
Dan SpiegelmanNamed on SEC filing
BS
Beth SpiegelmanNamed on SEC filing
FC
Fred CohenNamed on SEC filing
SL
Steve LiapisNamed on SEC filing
DB
Dominic BorieinStrategic Advisor2025–2026Chief Medical Officer and Head of Research and Development at Cue Biopharma
Investors · 8
Bain Capital Life SciencesBoston
Vida VenturesLos Angeles
Westlake Village BioPartnersLos Angeles · $100K – $5M
Gilead SciencesreportedFoster City
Kleiner PerkinsreportedMenlo Park · $500K – $15M
Oxford Finance LLCreportedAlexandria · $5M – $125M
RTW Investments L.P.reportedNew York
Westlake BioPartnersreportedWestlake Village
Reported raises · per SEC filings
Form D private placements$152M disclosed across 1 of 2 rounds · 1900–2021
▶$152MraisedNov 2023 · 24 investors · BiotechnologyRule 506(b)
▶$152MraisedNov 2023 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian KotzinDirector
- Ian ClarkDirector
- Ryan JonesExecutive Officer
- Karen WalkerExecutive Officer
- Peter MaagExecutive Officer, Director
- James ChungExecutive Officer
- Dan SpiegelmanDirector
- Beth SpiegelmanDirector
- Fred CohenDirector
- Steve LiapisDirector
- Dominic BorieExecutive Officer
- Offering amount
- $152M
- Amount sold
- $152M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$900.3Mvaluation at IPOFeb 2024 · $22.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 1
by search overlapCompanies competing with Kyverna Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Kyverna Therapeutics to Present at Upcoming September 2026 Investor Conferences - BioSpacebiospace.com · Sep 2026
Three fireside chats and investor meetings are scheduled in September for Kyverna managementstocktitan.net · Sep 2026Frequently asked questions
- What does Kyverna Therapeutics do?
- Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
- Who are Kyverna Therapeutics's investors?
- Kyverna Therapeutics's investors include Bain Capital Life Sciences, Vida Ventures, Westlake Village BioPartners, Gilead Sciences, Kleiner Perkins, Oxford Finance LLC, RTW Investments L.P., Westlake BioPartners.
- How much funding has Kyverna Therapeutics raised?
- Kyverna Therapeutics has disclosed $152M raised across 1 of its 2 known rounds.
- Where is Kyverna Therapeutics headquartered?
- Kyverna Therapeutics is headquartered in Emeryville, US.